Cargando…

Combination of molecularly targeted therapies and immune checkpoint inhibitors in the new era of unresectable hepatocellular carcinoma treatment

Multikinase inhibitors (MKIs) have been the only first-line treatment for advanced hepatocellular carcinoma (HCC) for more than a decade, until the approval of immune checkpoint inhibitors (ICIs). Moreover, the combination regimen of atezolizumab (anti-programmed cell death protein ligand 1 antibody...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Ze-Long, Liu, Jing-Hua, Staiculescu, Daniel, Chen, Jiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8150670/
https://www.ncbi.nlm.nih.gov/pubmed/34104226
http://dx.doi.org/10.1177/17588359211018026
_version_ 1783698203188658176
author Liu, Ze-Long
Liu, Jing-Hua
Staiculescu, Daniel
Chen, Jiang
author_facet Liu, Ze-Long
Liu, Jing-Hua
Staiculescu, Daniel
Chen, Jiang
author_sort Liu, Ze-Long
collection PubMed
description Multikinase inhibitors (MKIs) have been the only first-line treatment for advanced hepatocellular carcinoma (HCC) for more than a decade, until the approval of immune checkpoint inhibitors (ICIs). Moreover, the combination regimen of atezolizumab (anti-programmed cell death protein ligand 1 antibody) plus bevacizumab (anti-vascular endothelial growth factor monoclonal antibody) has recently been demonstrated to have superior efficacy when compared with sorafenib monotherapy. The remarkable efficacy has made this combination therapy the new standard treatment for advanced HCC. In addition to MKIs, many other molecularly targeted therapies are under investigation, some of which have shown promising results. Therefore, in the era of immuno-oncology, there is a significant rationale for testing the combinations of molecularly targeted therapies and ICIs. Indeed, numerous preclinical and clinical studies have shown the synergic antitumor efficacy of such combinations. In this review, we aim to summarize the current knowledge on the combination of molecularly targeted therapies and immune checkpoint therapies for HCC from both preclinical and clinical perspectives.
format Online
Article
Text
id pubmed-8150670
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-81506702021-06-07 Combination of molecularly targeted therapies and immune checkpoint inhibitors in the new era of unresectable hepatocellular carcinoma treatment Liu, Ze-Long Liu, Jing-Hua Staiculescu, Daniel Chen, Jiang Ther Adv Med Oncol Immunotherapy in Hepatocellular Carcinoma: a New Kid on the Block Multikinase inhibitors (MKIs) have been the only first-line treatment for advanced hepatocellular carcinoma (HCC) for more than a decade, until the approval of immune checkpoint inhibitors (ICIs). Moreover, the combination regimen of atezolizumab (anti-programmed cell death protein ligand 1 antibody) plus bevacizumab (anti-vascular endothelial growth factor monoclonal antibody) has recently been demonstrated to have superior efficacy when compared with sorafenib monotherapy. The remarkable efficacy has made this combination therapy the new standard treatment for advanced HCC. In addition to MKIs, many other molecularly targeted therapies are under investigation, some of which have shown promising results. Therefore, in the era of immuno-oncology, there is a significant rationale for testing the combinations of molecularly targeted therapies and ICIs. Indeed, numerous preclinical and clinical studies have shown the synergic antitumor efficacy of such combinations. In this review, we aim to summarize the current knowledge on the combination of molecularly targeted therapies and immune checkpoint therapies for HCC from both preclinical and clinical perspectives. SAGE Publications 2021-05-24 /pmc/articles/PMC8150670/ /pubmed/34104226 http://dx.doi.org/10.1177/17588359211018026 Text en © The Author(s), 2021 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Immunotherapy in Hepatocellular Carcinoma: a New Kid on the Block
Liu, Ze-Long
Liu, Jing-Hua
Staiculescu, Daniel
Chen, Jiang
Combination of molecularly targeted therapies and immune checkpoint inhibitors in the new era of unresectable hepatocellular carcinoma treatment
title Combination of molecularly targeted therapies and immune checkpoint inhibitors in the new era of unresectable hepatocellular carcinoma treatment
title_full Combination of molecularly targeted therapies and immune checkpoint inhibitors in the new era of unresectable hepatocellular carcinoma treatment
title_fullStr Combination of molecularly targeted therapies and immune checkpoint inhibitors in the new era of unresectable hepatocellular carcinoma treatment
title_full_unstemmed Combination of molecularly targeted therapies and immune checkpoint inhibitors in the new era of unresectable hepatocellular carcinoma treatment
title_short Combination of molecularly targeted therapies and immune checkpoint inhibitors in the new era of unresectable hepatocellular carcinoma treatment
title_sort combination of molecularly targeted therapies and immune checkpoint inhibitors in the new era of unresectable hepatocellular carcinoma treatment
topic Immunotherapy in Hepatocellular Carcinoma: a New Kid on the Block
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8150670/
https://www.ncbi.nlm.nih.gov/pubmed/34104226
http://dx.doi.org/10.1177/17588359211018026
work_keys_str_mv AT liuzelong combinationofmolecularlytargetedtherapiesandimmunecheckpointinhibitorsintheneweraofunresectablehepatocellularcarcinomatreatment
AT liujinghua combinationofmolecularlytargetedtherapiesandimmunecheckpointinhibitorsintheneweraofunresectablehepatocellularcarcinomatreatment
AT staiculescudaniel combinationofmolecularlytargetedtherapiesandimmunecheckpointinhibitorsintheneweraofunresectablehepatocellularcarcinomatreatment
AT chenjiang combinationofmolecularlytargetedtherapiesandimmunecheckpointinhibitorsintheneweraofunresectablehepatocellularcarcinomatreatment